JP2007505127A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505127A5
JP2007505127A5 JP2006526272A JP2006526272A JP2007505127A5 JP 2007505127 A5 JP2007505127 A5 JP 2007505127A5 JP 2006526272 A JP2006526272 A JP 2006526272A JP 2006526272 A JP2006526272 A JP 2006526272A JP 2007505127 A5 JP2007505127 A5 JP 2007505127A5
Authority
JP
Japan
Prior art keywords
tert
butyl
oxo
naphthalen
morpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006526272A
Other languages
English (en)
Japanese (ja)
Other versions
JP4895811B2 (ja
JP2007505127A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/029372 external-priority patent/WO2005023761A2/en
Publication of JP2007505127A publication Critical patent/JP2007505127A/ja
Publication of JP2007505127A5 publication Critical patent/JP2007505127A5/ja
Application granted granted Critical
Publication of JP4895811B2 publication Critical patent/JP4895811B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006526272A 2003-09-11 2004-09-10 サイトカイン阻害剤 Expired - Fee Related JP4895811B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US50256903P 2003-09-11 2003-09-11
US60/502,569 2003-09-11
US53123403P 2003-12-18 2003-12-18
US60/531,234 2003-12-18
US57570404P 2004-05-28 2004-05-28
US60/575,704 2004-05-28
US58501204P 2004-07-02 2004-07-02
US60/585,012 2004-07-02
PCT/US2004/029372 WO2005023761A2 (en) 2003-09-11 2004-09-10 Cytokine inhibitors

Publications (3)

Publication Number Publication Date
JP2007505127A JP2007505127A (ja) 2007-03-08
JP2007505127A5 true JP2007505127A5 (enExample) 2007-10-25
JP4895811B2 JP4895811B2 (ja) 2012-03-14

Family

ID=34280064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526272A Expired - Fee Related JP4895811B2 (ja) 2003-09-11 2004-09-10 サイトカイン阻害剤

Country Status (11)

Country Link
US (4) US7749999B2 (enExample)
EP (1) EP1670787B1 (enExample)
JP (1) JP4895811B2 (enExample)
CN (1) CN102060806A (enExample)
AU (1) AU2004270733B2 (enExample)
BR (1) BRPI0414313A (enExample)
CA (1) CA2538820A1 (enExample)
IL (1) IL174010A0 (enExample)
MX (1) MXPA06002853A (enExample)
SG (1) SG146624A1 (enExample)
WO (1) WO2005023761A2 (enExample)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
BRPI0416852A (pt) 2003-11-21 2007-02-27 Array Biopharma Inc inibidores da quinase akt
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US8178672B2 (en) 2004-10-19 2012-05-15 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase
JP2008523072A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ, インコーポレイテッド タンパク質キナーゼの阻害剤
JP2008523071A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ, インコーポレイテッド Mapキナーゼの尿素インヒビター
WO2006091862A2 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
US8242149B2 (en) * 2005-03-11 2012-08-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
DE602006018456D1 (de) * 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
WO2007007886A1 (en) 2005-07-11 2007-01-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
WO2007015877A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
RS51470B (sr) 2005-09-16 2011-04-30 Arrow Therapeutics Limited Derivati bifenila i njihova upotreba za lečenje hepatitisa c
WO2007035873A1 (en) * 2005-09-21 2007-03-29 Pharmacopeia, Inc. Purinone derivatives for treating neurodegenerative diseases
CA2624683A1 (en) * 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20100004248A1 (en) * 2005-10-24 2010-01-07 David Kass Use of a Nitric Oxide Synthase Modulator for the Treatment of Cardiac Indications
US20070243184A1 (en) * 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
WO2007058990A2 (en) * 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
NZ569327A (en) * 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP5131990B2 (ja) * 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤およびその使用方法
EP1986633B1 (en) 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
US8653275B2 (en) * 2006-05-12 2014-02-18 University Of Kentucky Research Foundation Bis-quaternary ammonium cyclophane compounds that interact with neuronal nicotinic acetylcholine receptors
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
EP2035005A4 (en) * 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080064626A1 (en) * 2006-09-08 2008-03-13 Zanella John M Methods of treating tendonitis in a subject by using an anti-cytokine agent
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
EP2086326B1 (en) * 2006-11-13 2014-01-08 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
WO2008084873A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
WO2008084872A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
WO2008089034A2 (en) * 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
ATE521609T1 (de) * 2007-05-04 2011-09-15 Astrazeneca Ab Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
WO2008141013A1 (en) * 2007-05-08 2008-11-20 Allergan, Inc. S1p3 receptor inhibitors for treating pain
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
WO2008147938A2 (en) * 2007-05-24 2008-12-04 Centocor, Inc. Wnt5a as an inflammatory disease marker
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
LT2170396T (lt) * 2007-08-03 2017-03-10 Summit (Oxford) Limited Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
AU2009231258A1 (en) * 2008-04-04 2009-10-08 Biomarin Iga Limited Compounds for treating muscular dystrophy
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
WO2009133834A1 (ja) * 2008-04-28 2009-11-05 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するケトアミド誘導体
CN102186809A (zh) 2008-08-14 2011-09-14 拜尔农作物科学股份公司 杀虫性的4-苯基-1h-吡唑
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
JP5603869B2 (ja) 2008-09-29 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
KR20100066868A (ko) * 2008-12-10 2010-06-18 동화약품주식회사 신규한 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2010067989A2 (ko) * 2008-12-10 2010-06-17 동화약품주식회사 신규한 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
KR20100066870A (ko) * 2008-12-10 2010-06-18 동화약품주식회사 신규한 6-인다졸릴아미노-3-니트로피리딘 유도체 화합물, 그의 제조방법 및 이를 포함하는 약제학적 조성물
WO2010067987A2 (ko) * 2008-12-10 2010-06-17 동화약품주식회사 신규한 2, 6-위치에 치환된 3-니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8569316B2 (en) 2009-02-17 2013-10-29 Boehringer Ingelheim International Gmbh Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
ES2547124T3 (es) 2009-04-02 2015-10-01 Merck Patent Gmbh Inhibidores de autotaxina
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ttk阻害作用を有するピリジンおよびピリミジン誘導体
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
EP2491033A4 (en) * 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
US20110117055A1 (en) * 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
CA2793170C (en) * 2010-03-15 2018-04-17 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B−rafキナーゼインヒビター
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
BR122019020471B1 (pt) 2010-04-19 2021-06-22 Oryzon Genomics S.A. Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas
US8551487B2 (en) * 2010-05-07 2013-10-08 Xoma Technology, Ltd. Methods for the treatment of IL-1β related conditions
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN102093394B (zh) * 2011-01-10 2012-11-21 中国药科大学 氯诺昔康氨丁三醇共晶
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
JP5855253B2 (ja) * 2011-08-12 2016-02-09 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft インダゾール化合物、組成物及び使用方法
UA116765C2 (uk) 2011-10-20 2018-05-10 Орізон Джіномікс, С.А. (гетеро)арилциклопропіламіни як інгібітори lsd1
CN104203914B (zh) 2011-10-20 2017-07-11 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
US9044408B2 (en) 2011-10-31 2015-06-02 Avon Products, Inc. Cosmetic use of N-heteroarylbisamide analogs and related compounds
RU2586333C1 (ru) 2011-12-09 2016-06-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта
SG11201405357SA (en) * 2012-03-01 2014-10-30 Array Biopharma Inc Crystalline forms of 1- (3 -tert-butyl- 1 - p-tolyl- 1h- pyrazol- 5 -yl) -3- (5-fluoro-2- (1- ( 2 - hydroxyethyl) - indazol- 5 -yloxy) benzyl) urea hydrochloride
ES2778701T3 (es) * 2012-07-13 2020-08-11 The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer Gestión de toxicidad para la actividad antitumoral de CAR
WO2014033449A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
EP2890460B1 (en) 2012-08-29 2017-02-22 Respivert Limited Kinase inhibitors
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
US10548994B1 (en) * 2013-03-11 2020-02-04 Stc.Unm Control of chronic neuropathic pain and allodynia
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
WO2014151729A1 (en) * 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
ES2702182T3 (es) 2013-03-15 2019-02-27 Verseon Corp Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
EP2981535B8 (en) 2013-04-02 2021-03-10 Oxular Acquisitions Limited Urea derivatives useful as kinase inhibitors
CN103740734B (zh) * 2013-07-01 2015-10-14 上海交通大学 厦门霉素生物合成基因簇、用途及菌株
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
MX367723B (es) 2013-10-25 2019-09-03 Novartis Ag Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4.
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
HRP20182021T1 (hr) 2013-12-19 2019-01-25 Novartis Ag Derivati [1,2,4]triazolo[1,5-a]pirimidina kao inhibitori proteazoma protozoe za liječenje parazitskih bolesti poput lišmenijaze
EP3083604A1 (en) 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
DK3113772T3 (da) 2014-03-07 2020-12-07 Biocryst Pharm Inc Trifluormethylsubstituerede pyrazoler som inhibitorer af kallikrein fra humant plasma
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CN107109420A (zh) 2014-07-21 2017-08-29 诺华股份有限公司 使用cll-1嵌合抗原受体的癌症治疗
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3200786B1 (en) 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
SG11201706411YA (en) 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
AU2016316683B2 (en) 2015-09-04 2020-07-23 The Johns Hopkins University Low-profile intercranial device
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3394033B1 (en) 2015-12-22 2020-11-25 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018067552A2 (pt) 2016-04-06 2019-01-08 Topivert Pharma Ltd inibidores de cinase
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
HUE054548T2 (hu) 2016-12-20 2021-09-28 Astrazeneca Ab Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
GB201700257D0 (en) 2017-01-06 2017-02-22 Atlantic Pharmaceuticals (Holdings) Ltd New formulation
DK3448859T3 (da) 2017-03-20 2019-09-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer
WO2019014352A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
PL4212529T3 (pl) 2018-03-30 2025-07-07 Incyte Corporation Związki heterocykliczne jako immunomodulatory
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
BR112020024879A2 (pt) 2018-06-07 2021-03-09 Idorsia Pharmaceuticals Ltd Composto, composição farmacêutica, uso de um composto, e, método
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
CN112654350A (zh) * 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼrの活性化
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
CN120365272A (zh) 2018-10-05 2025-07-25 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
EP3897592B1 (en) * 2018-12-17 2025-09-24 Godavari Biorefineries Ltd. Compounds for the inhibition of unregulated cell growth
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
AU2020211071A1 (en) 2019-01-23 2021-07-15 Novartis Ag New crystalline forms of a succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
CN111825605B (zh) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 芳基酮酰胺类化合物及其制备方法和用途
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
WO2021002887A1 (en) * 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
MX2022003254A (es) 2019-09-19 2022-04-18 Forma Therapeutics Inc Composiciones activadoras de piruvato cinasa r (pkr).
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
CR20220237A (es) 2019-11-11 2022-08-05 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
AR124001A1 (es) 2020-11-06 2023-02-01 Incyte Corp Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023154519A1 (en) 2022-02-14 2023-08-17 Accent Therapeutics, Inc. Inhibitors of rna helicase dhx9 and uses thereof
US12357843B2 (en) 2022-03-25 2025-07-15 Cutera, Inc. Methods of skin treatment with laser light

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1693010A1 (de) * 1967-03-20 1971-07-22 Ciba Geigy Ag Oxalsaeurediamid-Derivate als Ultraviolett-Absorber
GB1208015A (en) * 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US4029671A (en) * 1976-03-22 1977-06-14 Eli Lilly And Company 3-[(5-nitro-2-imidazolyl)pyrazol-5-yl]oxamic acid derivatives
EP0122155A3 (en) * 1983-04-12 1985-07-31 Eli Lilly And Company Improvements in or relating to naphthylglycyl cephalosporin derivatives
IT1183181B (it) 1985-02-07 1987-10-05 Corvi Camillo Spa Derivati del 3-metil-imidazo(4,5-c)pirazolo con attivita' terapeutica e procedimento per la loropreparazione
US4761424A (en) * 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
LU87821A1 (fr) 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5192770A (en) 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
FR2676439B1 (fr) 1991-05-13 1994-10-28 Cird Galderma Nouveaux composes bi-aromatiques derives d'un motif salicylique, leur procede de preparation et leur utilisation en medecine humaine et veterinaire ainsi qu'en cosmetique.
JPH05201980A (ja) 1992-01-30 1993-08-10 Mitsubishi Kasei Corp メトキシイミノ酢酸誘導体およびこれを有効成分とする農園芸用殺菌剤
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
FR2713637B1 (fr) 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
JPH07224041A (ja) 1994-02-10 1995-08-22 Mitsubishi Chem Corp ピラゾリル酢酸誘導体およびこれを有効成分とする農園芸用殺菌剤
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998046559A1 (en) 1997-04-16 1998-10-22 Arqule, Inc. SYNTHESIS AND USE OF α-KETOAMIDE DERIVATIVES AND ARRAYS
US6143931A (en) * 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays
AU7135598A (en) 1997-04-16 1998-11-11 Arqule, Inc. Synthesis and use of biased arrays
CA2308428A1 (en) 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US6358506B1 (en) * 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
AU1939999A (en) 1997-12-22 1999-07-12 Bayer Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DE69836563T2 (de) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TR200003130T2 (tr) * 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
EP1083918A1 (en) 1998-06-08 2001-03-21 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
WO2000016769A1 (en) 1998-09-24 2000-03-30 Bristol-Myers Squibb Company ACTIVE ENANTIOMER OF RARη-SPECIFIC AGONIST
AU761361B2 (en) 1998-09-25 2003-06-05 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
AU6060099A (en) 1998-09-30 2000-04-17 Procter & Gamble Company, The 2-substituted ketoamides
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
EP1022027A1 (en) 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
WO2000050425A1 (en) 1999-02-22 2000-08-31 Boehringer Ingelheim Pharmaceuticals, Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
GB9905579D0 (en) 1999-03-12 1999-05-05 Secr Defence Photoactive pentaerythritol derivatives and orientation layers
CN100352804C (zh) * 1999-03-17 2007-12-05 阿斯特拉曾尼卡有限公司 酰胺衍生物
JP2001031636A (ja) 1999-05-18 2001-02-06 Senju Pharmaceut Co Ltd α−ケトアミド誘導体およびその医薬用途
EP1196167B1 (en) 1999-07-02 2006-04-19 Stuart A. Lipton Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions
ATE312823T1 (de) * 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
WO2001010821A1 (en) 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent exocyclic diketo compounds
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
WO2001036403A1 (en) 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
DE19962300A1 (de) 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
PE20010830A1 (es) 2000-01-28 2001-09-06 Syngenta Ltd Derivados de azol insecticidas o fungicidas y composiciones que los comprenden
US6653304B2 (en) * 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
AU4316301A (en) * 2000-03-14 2001-10-08 Upjohn Co Novel 2,3,4,5-tetrahydro-1H-(1,4)diazepino(1,7a)indole compounds
DE10034880A1 (de) 2000-07-18 2002-02-07 Siemens Ag Dosiersystem
IT1318641B1 (it) 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
AU2002231283A1 (en) 2000-10-19 2002-04-29 Smith Kline Beecham Corporation Use of p38 inhibitors for the treatment of smoke inhalation
TWI262920B (en) * 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
US6821966B2 (en) 2000-11-20 2004-11-23 Scios, Inc. Inhibitors of p38 kinase
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
JP2004518739A (ja) 2001-02-15 2004-06-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤として有用なヘテロアリール置換尿素化合物の合成方法
GB2373245A (en) 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
WO2002083628A1 (en) 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused compounds
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
JP2004531571A (ja) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
WO2002098869A2 (en) 2001-06-05 2002-12-12 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
CA2451605C (en) 2001-06-20 2010-08-10 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
ATE401079T1 (de) * 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US7005081B2 (en) * 2001-07-05 2006-02-28 Canon Kabushiki Kaisha Base material cutting method, base material cutting apparatus, ingot cutting method, ingot cutting apparatus and wafer producing method
US6916814B2 (en) * 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
SI1409477T1 (sl) 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
JP2005503400A (ja) * 2001-09-13 2005-02-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介病の治療方法
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
JP2005506350A (ja) * 2001-10-18 2005-03-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物
US6562558B1 (en) * 2001-12-06 2003-05-13 Eastman Kodak Company Photographic element, compound, and process
US20030118575A1 (en) 2001-12-11 2003-06-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method for administering BIRB 796 BS
FR2834288B1 (fr) 2001-12-28 2011-12-16 Virbac Sa Procede de preparation de nouveaux derives n-substitues de 5-amino-phenylpyrazole, nouveaux derives n-substitues de 5-amino-phenylpyrazole et leur utilisation comme agents parasiticides et/ou insecticides
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
WO2003072569A1 (en) 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
US20030225089A1 (en) 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
US7960398B2 (en) * 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
JP2003335733A (ja) 2002-05-14 2003-11-28 Sugai Chemical Industry Co Ltd 1,4−アミノナフトール誘導体の製造方法
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
US20040044020A1 (en) * 2002-07-09 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
HRP20050201A2 (en) 2002-08-01 2005-04-30 Elbion Ag Method for producing highly pure hydroxy indolyl glyoxylic acid amideslyoxylic acid amides
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
DE10241407A1 (de) 2002-09-06 2004-03-18 Elbion Ag Behandlung nicht allergischer Rhinitis durch selektive Phosphodiesterase 4-Hemmstoffe
KR20050052498A (ko) 2002-09-13 2005-06-02 신타 파마슈티칼스 코프. 인돌리진의 합성
US7115644B2 (en) * 2002-09-13 2006-10-03 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
WO2004058724A1 (ja) 2002-12-25 2004-07-15 Sumitomo Chemical Company, Limited フェニルピラゾール化合物及びそれを用いた植物病害の防除方法
RU2357957C2 (ru) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
WO2004083193A1 (ja) 2003-03-17 2004-09-30 Sumitomo Chemical Company, Limited アミド化合物およびこれを含有する殺菌剤組成物
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
AU2005212419B2 (en) * 2004-02-10 2008-11-20 Graphic Packaging International, Inc. Carton having opening and positioning features

Similar Documents

Publication Publication Date Title
JP2007505127A5 (enExample)
US7749999B2 (en) Alpha-ketoamides and derivatives thereof
JP5555169B2 (ja) 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
US6150385A (en) 1,3,4-thiadiazoles useful for the treatment of CMV infections
JP2009503107A5 (enExample)
CA2582029A1 (en) Aryl nitrogen-containing bicyclic compounds and methods of use
HRP20130220T1 (hr) Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
AU1997199A (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
JP2012515724A5 (enExample)
US20120149706A1 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
HRP20130865T1 (hr) Derivati pirazol piridina kao inhibitori nadph oksidaze
HRP20130972T1 (hr) Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti
PT1725544E (pt) 3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas
CA2536954A1 (en) C-kit modulators and methods of use
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy
JP2013517273A5 (enExample)
WO2007058990A2 (en) Therapy using cytokine inhibitors
RU2006106849A (ru) Ингибиторы цитокинов
US20100184774A1 (en) Methods of treatment
ZA200602080B (en) Cytokine inhibitors
KR890007732A (ko) 진경제, 근육이완제 및 불안해소제용 3-아미노-5-메틸-1h-피라졸-4-카복실산 및 이의 에스테르
PL4225306T3 (pl) Zastosowanie soli siarczanowych n‐(3‐(4‐(3‐(diizobutyloamino)propylo)piperazyn‐1‐ylo)propylo)‐1h‐benzo[d]imidazolo‐2‐aminy i ich solwatów do leczenia chorób neuronu ruchowego i zaburzeń płytki nerwowo-mięśniowej
KR101170175B1 (ko) 사이토킨 억제제
HK1091210B (en) Cytokine inhibitors